Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside Academic Article uri icon

Overview

MeSH Major

  • BCG Vaccine
  • G(M2) Ganglioside
  • Melanoma

abstract

  • (1) Vaccination with GM2/BCG induced immunoglobulin M (IgM) antibodies in most patients. (2) GM2 antibody production was associated with a prolonged disease-free interval and survival. (3) Comparison of the two arms of this trial as randomized fails to show a statistically significant improvement in disease-free interval or survival for patients treated with GM2/BCG vaccines.

publication date

  • May 1994

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 8164027

Additional Document Info

start page

  • 1036

end page

  • 44

volume

  • 12

number

  • 5